NIH Announces Funding Opportunity

The National Institutes of Health announced a new funding opportunity of interest to the thalassemia community on May 1, 2009. Below is information from that announcement.



Purpose. This Funding Opportunity Announcement (FOA) is a call for the application of imaging and other non- or minimally-invasive technologies to detect, characterize, diagnose, identify persons with predisposition to, or monitor treatment of diseases of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Also needed are new, robust surrogate markers for clinical trial endpoints, and new ways to characterize normal and pathological tissues in vivo. Diseases of interest include type 1 and 2 diabetes; acute and chronic kidney disease, liver, urologic, hematologic, digestive, endocrine, and metabolic diseases and their complications; obesity; obesity-related hypertension, hypertension, renal and vascular disorders leading to hypertension. Applicable techniques include molecular imaging and functional imaging approaches, imaging methods with high spatial, chemical or time resolution, metabolomics, proteomics, genomics, or new spectroscopic or sensor array technologies for monitoring metabolic or physiological events. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Developmental/Exploratory Research (R21) applications within the scientific scope of the FOA can be submitted in response to the NIH Parent R21 PA, http://grants.nih.gov/grants/guide/pa-files/PA-09-164.html.
Non-Invasive Methods for Diagnosis and Progression of Diabetes, Kidney, Urological, Hematological and Digestive Diseases and Hypertensive Disorders (R01)